Screener
Viking Therapeutics VKTX Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
| Revenues | Three Months Ended March 31, 2026 / — | Three Months Ended March 31, 2025 / — |
|---|---|---|
| Amortization of financing costs | — | (24) |
| Interest income, net | 5,800 | 9,864 |
| Total other income, net | 5,800 | 9,840 |
| Net loss | (158,325) | (45,629) |
| Other comprehensive loss, net of tax: | ||
| Unrealized (loss) gain on securities | (1,250) | 563 |
| Foreign currency translation gain | 16 | 9 |
| Comprehensive loss | $(159,559) | $(45,057) |
Item 1. Financial Statements
FAQ
- What is Viking Therapeutics's net income?
- Viking Therapeutics (VKTX) reported net income of -$158.33M in Q1 2026.
- How has Viking Therapeutics's net income changed year-over-year?
- Viking Therapeutics's net income decreased by 247.0% year-over-year, from -$45.63M to -$158.33M.
- What is the long-term trend for Viking Therapeutics's net income?
- Over 4 years (2021 to 2025), Viking Therapeutics's net income has grown at a 59.9% compound annual growth rate (CAGR), from -$54.99M to -$359.64M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Viking Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude